New Journey(002219) 首创证券·2024-08-07 08:03Investment Rating - The report assigns a "Buy" rating for the company [1][3]. Core Views - The company is demonstrating confidence in its future development through a share buyback plan, intending to repurchase shares at a price not exceeding RMB 2.74 per share, with a total value between RMB 50 million to 100 million [1]. - The medical services segment is showing steady growth, with Q1 2024 revenue reaching RMB 740 million, a year-on-year increase of 5.62% [2][3]. - The company is actively expanding its hospital network, with new facilities expected to enhance bed utilization rates and overall revenue [2][3]. - The pharmaceutical segment is also performing well, with a 45.24% increase in revenue to RMB 121 million in Q1 2024, driven by strategic acquisitions [2][3]. Summary by Sections Company Overview - The latest closing price is RMB 2.24, with a one-year high of RMB 3.90 and a low of RMB 1.66 [2]. - The current price-to-earnings (PE) ratio is 228.40, and the price-to-book (PB) ratio is 3.40 [2]. Financial Performance - Revenue projections for 2024 to 2026 are RMB 4.006 billion, RMB 4.484 billion, and RMB 5.004 billion, with year-on-year growth rates of 11.6%, 11.9%, and 11.6% respectively [3]. - The net profit attributable to the parent company is expected to rise significantly, from RMB 143 million in 2024 to RMB 350 million in 2026, reflecting growth rates of 362.7%, 78.5%, and 37.5% [3]. - Earnings per share (EPS) is projected to increase from RMB 0.04 in 2024 to RMB 0.10 in 2026 [3]. Business Segments - The medical services segment is expected to benefit from both organic growth and external expansion, with ongoing projects to increase hospital capacity [2][3]. - The pharmaceutical segment is leveraging acquisitions to enhance its market position and revenue potential [2][3].